

24 Abstract 300/300

25 **Introduction:** In pediatric intensive care units, pain, sedation, delirium, and iatrogenic withdrawal syndrome
26 must be managed as interrelated conditions. Existing clinical practice guidelines have some methodological
27 limitations and are not readily transferrable to the European context without adaptation. This protocol
28 describes the methods for developing a high-quality, and the first patient- and family-informed European
29 guideline for managing pain, sedation, delirium and iatrogenic withdrawal syndrome.

30 **Methods:** The guideline will be developed using the Grading of Recommendations Assessment,
31 Development and Evaluation (GRADE) - ADOLOPEMENT approach, engaging clinical experts and
32 patients and families in the development process. It will consist of seven phases: 1) Set-up – establishing
33 three groups for guideline development: i) steering committee, ii) development panel (experts and
34 patient/family partners from across Europe), and iii) patient and family advisory panel, and scoping to
35 determine population, conditions, purpose, and users of the guideline; 2) Preparation – voting on summary
36 recommendations, prioritizing research questions and outcomes, and matching research questions with
37 existing recommendations; 3) Search and retrieval of evidence – using three search approaches to develop
38 search strategies to find evidence, conducting individualized searches for each summary recommendation
39 and new research question, selecting evidence, study appraisal, and initial data extraction; 4) Evidence
40 synthesis – summarizing evidence in evidence profiles and summary of evidence tables, and conducting
41 panel surveys of current practice when evidence is absent; 5) Development – drafting recommendations,
42 voting on and approving them, and developing accompanying materials; 6) Review – conducting internal,
43 society-level, and external international expert reviews; and 7) Issue – publishing the guideline.

44 **Discussion:** This protocol ensures a transparent process follows the GRADE approach for guideline
45 development, leading to a high-quality, trustworthy, and credible guideline for managing pain, sedation,
46 delirium and iatrogenic withdrawal syndrome in critically ill children. Tailored to the European context for
47 healthcare professionals.

48 **Registration:** Practice guideline REgistration for transPAREncy (PREPARE) registration number

49 PREPARE-2024CN859

50 **Keywords:** Assessment – Pediatric intensive care – Treatment – Critical care – Comfort

51 **Introduction** (word count: 5,245 (including table but excluding references))

52 Analgesia and sedation in critically ill children remain challenging for healthcare professionals in
53 pediatric intensive care units (PICUs), due to the heterogeneous responses of patients to the same
54 medications and the potential for drug side effects [1]. Suboptimal sedation can cause discomfort, agitation
55 and increased medication use [2]. While oversedation may cause complications like diaphragm dysfunction,
56 hemodynamic instability, altered bowel function, increased morbidity risk, and prolonged PICU stay [2, 3].
57 Undersedation can increase anxiety, stress, and the risk of accidental medical equipment removal, including
58 unplanned extubation [2, 4]. Prolonged use of analgesics and sedatives is associated with iatrogenic
59 withdrawal syndrome (IWS) and delirium [5, 6], both having long-term cognitive, emotional, and social
60 impairment in children, and causing significant distress for families [7, 8]. Therefore, achieving optimal
61 analgesation levels in critically ill children is fundamental for their comfort and safety with close
62 monitoring.

63 Accurate assessment is a prerequisite for appropriate management. The 2016 European Society of
64 Pediatric and Neonatal Intensive Care (ESPNIC) recommendations emphasized the importance of using
65 validated measurement instruments to monitor pain, depth of sedation, delirium, and IWS [9]. However,
66 recent surveys have highlighted wide variations in assessment practices and choice of drugs for managing
67 pain, sedation, delirium, and IWS (hereafter, referred to as the four conditions) [10-12]. Additionally,
68 compliance with these recommendations has been inconsistent, with up to 69% of clinicians not selecting the
69 correct measurement instruments, 30% misapplying them , and 3-58% not using them at all [13], leading to
70 potential under- or over-use of medications and adverse events.

71 To improve assessment and management practices, clinical practice guidelines (CPGs) have been
72 developed to synthesize evidence into evidence-based recommendations [14]. Although two CPGs for
73 managing pain, sedation, delirium, and IWS were published in 2022, they do not incorporate newer
74 pharmacological approaches and have outdated or flawed literature searches [15-17]. Our systematic review
75 found variability in the quality and evidence supporting recommendations in the included CPGs. While some
76 recommendations were supported by strong evidence, others, especially those related to delirium, lacked

77 support [17]. Furthermore, only 22% of the CPGs (n = 4) used the recommended Grading of
78 Recommendations Assessment, Development and Evaluation (GRADE) approach, which is important for
79 quality CPGs [18]. Among the shortcomings in the use of GRADE in these CPGs were, limited use of PICO
80 questions (50%), absence of prioritized outcomes (100%), and the absence of available evidence to decision
81 (EtD) tables (100%) [17, 19]. A recent narrative review highlighted 15 gaps in current CPG
82 recommendations that need addressing in future CPGs [20]. These limitations and emerging new evidence,
83 underscore the need for updating and contextualizing existing evidence into a new CPG. Therefore, we aim,
84 with the endorsement of ESPNIC, to develop a comprehensive and trustworthy CPG for managing pain,
85 sedation, delirium, and IWS in Europe.

86 **Methods**

87 The protocol for developing our CPG was registered in the Practice guideline REgistration for
88 transPAREncy (PREPARE) under registration number PREPARE-2024CN859. The GRADE-
89 ADOLOPMENT approach will be used for adopting, adapting, and developing de novo recommendations
90 based on prioritized research questions and outcomes, and matching recommendations from existing CPGs
91 [21]. This approach involves seven phases, ten steps, and 22 actions, summarised in Fig 1 and described
92 below. As no reporting checklist exists for guidelines, one was developed using Xun et al. [22] (S1 File).

93 **Fig 1:** Phases, steps, and actions of the guideline development process.

94 **Phase 1: Set-up**

95 The set-up phase comprises two steps and five actions.

96 **Step 1: Establish groups: steering committee, development and advisory panels**

97 Three groups will be formed: the steering committee, the development panel, and the patient and
98 family partner (PFP) advisory panel.

99 *Action 1 – Formalize the steering committee:* The steering committee includes a pediatric intensivist (AA), a
100 PICU nurse and researcher (ASR), and a nurse methodologist (IMD). The steering committee will oversee,

101 organize, and coordinate the development process. Committee members (ASR, AA) are institution-supported
102 and receive no funding for their work, while the chair (IMD) is supported by a postdoctoral fellowship for
103 her role and will also take on all administrative support tasks. An invited guest to the steering committee will
104 be the lead health sciences information specialist (ACT), who will assist with planning and conducting the
105 literature reviews.

106 Action 2 – Establish development panel:

107 The development panel will include clinical experts and Patient and Families Partners.

108 A. Clinical expert members. In April 2023, a call for expressions of interest to join the development
109 panel was sent to the Analgo-sedation Consortium from the Pharmacology and the Nursing Science Sections
110 of ESPNIC. Interested members completed a declaration of interest and conflict of interest (COI) form (S2
111 File). However, recruitment is ongoing. The expert panel will include nurses, intensivists, and pharmacists
112 from as many European countries as possible, all of whom will volunteer their time.

113 B. PFP members. PFPs who have specific experience with one or more aspects of the CPG will be
114 involved and engaged in the different steps of the development process as development panel members.
115 Recruitment of all PFPs is explained in Action 3.

116 Action 3 – Patient and Family involvement and engagement: Expert panel members will identify families
117 and/or patients from their existing networks and provide them with an information sheet (File S3) and an
118 expression of interest form that includes COI (File S4) [23-27]. If translation of these forms is required, an
119 established translation method will be used by the bilingual native-speaking expert panel member [28].
120 Interested patients and family members will be able to choose to join either the development panel or the
121 PFP advisory panel, depending on their level of comfort with English and willingness to engage. They will
122 indicate their group preference on the expression of interest form.

123 PFPs on the development panel will be compensated at an hourly rate for their participation in panel
124 meetings. For tasks outside of meetings, such as voting and reviewing, all PFPs will receive compensation on
125 a flat rate basis. The compensation was determined by averaging the compensation rates used by represented

126 countries and by referring to recommendations from the National Institute for Health and Care Research
127 [29]. PFP compensation is provided by ESPNIC.

128 The roles, responsibilities, and level of engagement and involvement across the three groups are
129 outlined in Table 1

130 **Table 1: Roles and responsibilities of the three groups.**

	Steering committee	Development panel	PFP advisory panel
Role	Oversees and coordinate the guideline’s development and ensures all preparatory tasks are completed.	Extensive discussions to draft, revise, and formalize the guideline.	Provides patient and family perspectives, confirms decisions, and reviews the guideline.
Responsibilities			
Purpose, scope, population	Draft	Establish	Advise and validate
Vote on summary recommendations	No	Yes	Advise and validate
Prioritize new research questions	No	Yes	Advise and validate
Prioritize outcomes for effectiveness questions	No	Yes	Yes
Update systematic review of guidelines	Yes	No	No
Match research questions to recommendations	Yes	No	No
Update searches Screen title- abstract, full text	Yes	Yes	No
Appraise studies	Yes	Yes	No
Data extraction	Yes	Yes	No
Create evidence summaries	Draft	Review and revise	Review and provide input from patients and family perspective
Formulate recommendations	Draft	Pairs - Revise to formalize	Provide input and confirm
Vote on drafted recommendations	No	Subgroups - Yes	Yes
Write guideline	Draft	Subgroups – draft and revise	No
Create accompanying materials	Draft	Draft	Possibly draft
Review guideline	Yes	Yes	Yes, if able

131 PFP: Patient and family partner, NA: Not applicable, EtD: evidence to decision.

132 All members of the development panel will complete a COI form covering financial, academic,
133 clinical, and community aspects [30]. At the beginning of each development panel meeting, the steering
134 committee chair will ask if any member have changes to their COI to declare. If yes, a new COI form will be

135 completed. The steering committee will monitor COIs, members with a declared COI will not participate in
136 the development or voting on recommendations related their COI.

137 Ethical approval will not be sought as no direct data from patients or clinicians will be used; instead,
138 their experiences will be used to inform the guideline. Completion of the expression of interest form will
139 signify consent to participate in the development of the guideline. If children are interested in participating in
140 either panel, their parents will also complete an expression of interest form and will participate alongside
141 them.

142 Training will be provided either during panel meetings or through available online resources [31-33].

143 **Step 2: Scoping the guideline**

144 Action 4 – Scoping: The population, condition, purpose, and users of the CPG will be determined during the
145 first online meeting with the expert panel members of the development panel.

146 Action 5 – Input and validation: Results of Action 4 will be sent to all PFPs for review, input, and validation
147 via SurveyMonkey [34]. PFPs will indicate whether they “reject”, “accept”, or “accept with modifications”
148 each element, providing rationale or indicating desired changes. A percentage for acceptance or rejection
149 will be calculated for each element, with a consensus of 80% or more required for confirmation. The steering
150 committee will review and revise as needed and will present these at the next development panel meeting.

151 **Phase 2: Preparation**

152 The preparation phase includes two steps and six actions.

153 **Step 3: Voting and prioritization**

154 Action 6 – Voting on summary recommendations: The 30 summary recommendations synthesized in our
155 systematic review of CPGs [17] were chosen for voting because they were featured across multiple CPGs.
156 Additionally, their supporting evidence was reviewed, along with harmonizing their strength of
157 recommendations and certainty of evidence [17]. These summary recommendations will be added to
158 SurveyMonkey [34], with an open-ended question asking about clinical areas where recommendations are

159 needed or lacking (see Action 7 below). Each member will select to either “accept (adopt)”, “reject”, or
160 “accept with modifications (adapt)” each recommendation. If modifications are needed, members will be
161 asked to specify them. Responses will be tallied, with “accept” and “accept with modifications” being
162 grouped together. A consensus of 80% or more will be needed for inclusion. Recommendations that fail to
163 meet this threshold will be discussed during a consensus meeting with the development panel, where a
164 decision will be made.

165 Action 7 – Research question prioritization: A list of research questions will be created based on the gaps
166 identified by Mondardini and colleagues [20], and areas without recommendations from the earlier survey
167 (Action 6). These questions will be entered into GRADEpro GDT (Guideline Development Tool) [35], an
168 online tool that assists development panels in brainstorming, prioritizing questions and outcomes, and
169 creating evidence to decision (EtD) tables. These EtD tables summarize evidence and present benefits, risks,
170 and other factors to support development panels in forming recommendations [21]. The prioritization
171 process, in GRADEpro GDT, involves the following steps:

- 172 1. Consolidation and reformulation: The steering committee will consolidate the questions by removing
173 duplicates, and where possible, reformatting them into PICO (patient, intervention, comparator,
174 outcome) effectiveness questions [36]. Nonactionable or descriptive questions will also be included.
- 175 2. Brainstorming: Development panel members will independently review and comment on the
176 questions and suggest new questions if needed.
- 177 3. Second consolidation: The steering committee will refine and reformat questions from the
178 brainstorming round to prepare for voting.
- 179 4. Voting: Development panel members will independently rate the importance of each question on a
180 9-point Likert-scale (1-3: non-important, 4-6: important, 7-9: critically important). GRADEpro GDT
181 will calculate mean scores and rank the questions from highest to lowest [35].
- 182 5. Decision-making: The steering committee will review the voting results and make decisions based
183 on the mean score for each question: reject (mean 1-3), answer (mean 7-9), or list for potential
184 inclusion in a future CPG (mean 4-6).
- 185 6. Approval: Development panel members will review and approve the decisions made in step 5.

186 7. Finalize: GRADEpro GDT will generate a matrix showing the percentage approval for each question
187 [35]. Questions with > 80% agreement will be retained.

188 Action 8 – PFP input and validation: The final list of retained summary recommendations (Action 6) and
189 research questions (Action 7) will be sent to PFPs using SurveyMonkey [34]. They will confirm their
190 agreement by selecting: “Yes”, “No”, or “Yes with modification”. PFPs can also propose new questions if
191 they believe any are missing. A consensus of 80% or more is needed to retain questions and
192 recommendations. The steering committee will review and revise based on suggested modifications, and
193 results will be discussed during the next development panel meeting.

194 Action 9 – Outcome prioritization: This step focuses on prioritizing outcomes for effectiveness questions,
195 excluding nonactionable/descriptive questions. This process mirrors Action 7, using GRADEpro GDT:

- 196 1. Brainstorming: The steering committee will generate a list of important outcomes for the PICU from
197 the literature [17, 37-39]. Outcomes will be assigned to each question, and the development panel
198 will independently review these and can suggest others.
- 199 2. Condense: The steering committee will review and consolidate outcomes as needed.
- 200 3. Voting: The development panel members will independently rate the importance of each outcome to
201 each question using the 9-point Likert scale in GRADEpro GDT. Simultaneously, PFPs will rate the
202 same questions and outcomes via a survey in SurveyMonkey [34] to ensure patient and family
203 perspectives.
- 204 4. Decision-making: The steering committee will review the voting results and make decisions based
205 on the mean score for each outcomes to: reject (mean 1-3), include in EtD table (mean 7-9), or to list
206 the outcome in the body/text for that research question (mean 4-6). A maximum of seven outcomes
207 can be included in EtD tables per question [40, 41]; in the event of more than seven being identified
208 as critically important (mean 7-9), responses between experts and PFP will be compared and PFP
209 responses will be prioritized when there are significant differences.
- 210 5. Approval: Development panel members will review and approve the decisions made in step 4.

211 6. Finalize: The approval matrix will be used to determine outcome inclusion, with at least 80%
212 agreement needed to be retained.

213 **Step 4: Recommendation Matching**

214 The cornerstone of the GRADE-ADOLOPMENT approach is adopting and adapting
215 recommendations from existing CPGs by matching them to questions [21]. This process involves evaluating
216 the relevance, applicability, and strength of the original recommendations [21].

217 Action 10 – Update of CPG systematic review: To ensure a current list of recommendations for matching
218 with questions (Action 9), we will update our systematic review of CPGs for managing the four conditions
219 following the same methods used previously [17].

220 Action 11 – Matching research questions with existing recommendations: The steering committee members
221 will assess whether each prioritized question matches any existing recommendations from the six selected
222 CPGs [9, 15, 16, 42-44] from our systematic review [21]. A match is required with the population,
223 intervention and comparator, and at least one shared outcome. This step will help establish the searches in
224 phase 3.

225 **Phase 3: Search and retrieval**

226 **Step 5: Systematic search for evidence**

227 This phase involves systematic searching for evidence using three distinct search approaches, based
228 on the strength of recommendations from the summary recommendations and matched recommendations
229 (Search approaches 1 and 2), and for unmatched or new questions (Search approach 3), as illustrated in Fig
230 2.

231 **Fig 2:** Three search approaches.

232 Action 12 – Develop search strategies:

233 *Search approach 1:* For recommendations with a strong or conditional strength, a search for systematic
234 reviews will be conducted.

235 *Search approach 2:* For recommendations with inconclusive and inconsistent strength, a search for
236 systematic reviews and primary studies will be completed.

237 Both search approaches (1 and 2) will limit results to the last 5 years to ensure up-to-date evidence.

238 *Search approach 3:* For new and unmatched questions, or summary recommendations needing extensive
239 modifications, a combined search for CPGs, systematic reviews, and primary studies will be conducted, with
240 a limit of the last 10 years.

241 The three different search approaches are necessary to ensure that the most up-to-date evidence is
242 incorporated into existing recommendations based on their current strength, while ensuring that all relevant
243 evidence is retrieved for new or unmatched questions. These approaches will provide the foundation for
244 developing comprehensive, tailored search strategies relative to study designs that help to either strengthen
245 recommendations (Search approaches 1 and 2) or for determining the level of evidence for new questions
246 (Search approach 3).

247 The search strategies for each summary recommendation and research question, developed based on
248 one of the three search approaches, will be conducted in four electronic databases: Medline ALL (Ovid),
249 Embase.com, CINAHL with Full Text (EBSCO), and Epistemonikos.

250 To update the evidence for each summary recommendation, the summary recommendation will be
251 transformed into a research question. These questions and new questions will all have customized search
252 strategies developed by a steering committee member (IMD) in consultation with a health sciences librarian
253 (ACT or CJ) using index and free-terms describing the condition of interest, the population of interest
254 (children aged 0 to 18 years), the comparison, and outcome. Another health services librarian will peer
255 review each search strategy per question using the PRESS checklist [45].

256 No language restrictions will be applied, non-English studies will be translated using a standardized
257 method [28], DeepL [46] to translate and then verification by a native speaker on the development panel or
258 finding one via panel members' networks. If one cannot be found, the study will not be included.

259 Action 13 – Execute search and selection:

260 For each search, the selection process will involve the retrieved records being imported into Endnote
261 20 (Clarivate Analytics, USA) and duplication by using Deduplick's automated algorithm [47]. Screening
262 and full-text review will be independently conducted by two reviewers from either the steering committee or
263 the development panel using Rayyan QCRI (Qatar Computing Research Institute, Doha, Qatar) [48].
264 Disagreements will be resolved through consensus or by a third reviewer.

265 Action 14 – Study appraisal: Appraisal will be based on study type: systematic reviews, primary studies, or
266 CPGs, and will be conducted by two independent appraisers.

267 *Systematic reviews.* Quality will be assessed using A Measurement Tool to Assess systematic Reviews 2
268 (AMSTAR 2), which includes 16 items to determine overall quality ranging from critically low to high based
269 on the presence of critical flaws [49]. Moderate and above studies will be retained.

270 *Primary studies.* The JBI checklists will be used to assess the quality of primary studies: Randomized
271 control trials [50], quasi-experimental studies [51], qualitative research [52], prevalence studies [53], cohort
272 studies [54], economic evaluations [55], diagnostic test accuracy studies [56], case reports [54], case control
273 studies [54], and analytical cross sectional studies [54]. Each appraiser determines the level of bias for each
274 item and an overall appraisal to include, exclude or needing more information.

275 *CPGs.* The AGREE II, a 23-item validated appraisal instrument will be used to evaluate the quality of CPGs
276 7-point Likert scale across six domains [57], scores are summed across appraisers, and if domain 3 (rigor of
277 development) > 60% the CPG will be retained.

278 The literature will continue to be monitored by monthly saved searches and added, up until the
279 development panel completes its final voting on recommendations (Action 19).

280 *Action 15 – Data extraction and initial synthesis:* Two members will independently extract data from each
281 study and verify the others, using a predefined, pilot-tested Excel sheet. For effectiveness questions,
282 outcomes will be extracted as means for potential meta-analysis if at least three studies exist with outcomes
283 data. If median and interquartile range (IQR) are reported, Wan's method and Excel tool will be used to
284 transform these into means [58].

285 Meta-analyses will be conducted using STATA version 17 software [59]. Random-effects models
286 applying the Sidik-Jonkman method, will be used with standard mean difference for continuous or odds
287 ratios for dichotomous variables. The I^2 test will be used to assess statistical heterogeneity, considered low if
288 $< 40\%$, moderate at $30\% - 60\%$, substantial at $50\% - 90\%$, and considerable at $75\% - 100\%$ [18]. If
289 heterogeneity is $\geq 40\%$, a sensitivity analysis will be performed by removing one study at a time to assess its
290 influencer on the overall effect size [18]. Additionally, sensitivity analysis will be performed on PICO
291 elements, study design, or risk of bias if sufficient studies (>2) are available to explore these other sources of
292 heterogeneity. Results will be presented as forest plots. To explore publication bias funnel plots will be used,
293 with Egger's test for type I error [60]. If meta-analysis is not possible, results will be described narratively.

294 **Phase 4: Evidence synthesis**

295 **Step 6: Evidence synthesis**

296 *Action 16 – Summarizing the evidence:* The GRADE approach focuses on using the best available high
297 quality evidence, typically from systematic reviews [18]. This involves developing two types of GRADE
298 evidence tables [19]:

299 1) EtD profiles: Provide information about the body of evidence and the judgements made about the
300 quality of evidence, included as statistical results for each outcome, per question [19]. These are completed
301 at the end of Phase 3 by the two reviewers using GRADEpro GDT. The categories addressed by these tables
302 include: outcomes, number of studies, study design, evidence quality factors, risk, effect, and overall quality
303 of evidence (high, moderate, low, or very low). Evidence quality is determined by reviewing five factors that
304 can lead to downgrading (risk of bias [61], inconsistency [62], indirectness [63], imprecision [64], and
305 publication bias [65]), and three factors that can lead to upgrading (large magnitude of effect, dose–response

306 gradient, and when all plausible confounders increase the confidence in the effect) [18, 66, 67]. These are
307 used to create the summary of findings (SoF) tables.

308 2) SoF tables: These simplified tables summarize the EtD tables without judgment details and will
309 include information on other factors like health benefits and harms, equity, feasibility, acceptability, and cost
310 [19, 21]. The steering committee will assign two development panel members to each question and summary
311 recommendation based on domain of expertise to complete the SoF tables.

312 For nonactionable/descriptive questions, narrative evidence profiles will be created. For summary
313 recommendations, evidence profiles will be created using both the originally cited literature and the studies
314 identified in the updated searches.

315 *Action 17 – Survey of current practice in absence of evidence:* If search results for a specific question reveal
316 little to no supporting evidence, the steering committee will develop a survey with open-ended questions to
317 gather information on current practices of development panel members, emphasizing cases and outcomes
318 [68, 69]. The results will be included in an EtD table and will be presented and discussed by the development
319 panel.

320 **Phase 5: Development**

321 The development phase includes two steps and four actions.

322 **Step 7: Recommendation development**

323 The recommendation development process will include several steps:

324 *Action 18 – recommendation drafting:*

325 1. Draft recommendations: The steering committee will draft recommendations based on the evidence
326 profile, and will reword summary recommendations, incorporating modifications suggested during
327 Action 6. Recommendations will be categorized as: **Strong:** Desirable effects outweigh undesirable
328 effects, applicable to almost all patients, **Conditional:** Desirable effects probably outweigh
329 undesirable effects, applicable to most patients but sensitive to preferences, or **Good Practice**
330 **statements:** Highly relevant with benefits far outweighing harms, even with indirect supporting
331 evidence [66]. Drafts will be sent to the pairs of panel members responsible for each specific
332 question or recommendation (see below point 3).

- 333 2. Recommendation table creation: Each development panel pair will complete the recommendation
334 table (File S5) for their assigned question or recommendation. The table includes the
335 recommendation, its direction (for or against), its strength (recommend or suggest), balance of
336 consequences, justification, considerations for subgroups (different populations or conditions),
337 implementation considerations, monitoring and evaluation criteria, and identified research gaps.
338 Recommendations for any accompanying documents or materials will be sent to the steering
339 committee (i.e., resources for implementation, patient information sheet, monitoring criteria).
- 340 3. Subgroup review: The steering committee will form subgroups focused on pain, sedation, delirium,
341 and IWS. Each subgroup includes pairs assigned to included questions and recommendations.
342 Subgroups will meet to review, revise the evidence tables, and update the recommendation table for
343 those that were assigned. A steering committee member will be present to address methodology
344 questions. The goal is to reach consensus of at least 80% on the wording, direction, and strength of
345 each recommendation. If consensus is not reached, this recommendation will be discussed at the next
346 development panel meeting.

347 Action 19 – recommendations voting and approval:

- 348 4. Recommendation approval voting #1: The recommendations and related tables (EtD, SoF, and
349 recommendation) will be sent to all development panel members for review at least two weeks
350 before the next panel meeting. During the meeting, members will vote to “accept”, “reject”, or
351 “accept with modifications”. At least 80% of panel members must be present to commence voting,
352 with an 80% consensus required to approve a recommendation.
- 353 Recommendations not reaching 80% approval will require further subgroup revision and voting until
354 80% approval is achieved.
- 355 5. Recommendation review by PFP advisory panel: The final list of approved recommendations will be
356 sent to the PFP advisory panel using SurveyMonkey for review and comment. They will be asked to
357 “accept” or “suggest modifications” for each recommendation.
- 358 6. Recommendation finalization: Any suggested modifications will be discussed at the next scheduled
359 development panel meeting, followed by a final round of voting to approve and finalize
360 recommendations.

361 **Step 8: Drafting CPG and accompanying content**

362 *Action 20 – Draft guideline*

363 Once recommendations are finalized, each recommendation pair will draft their section for the CPG.
364 This will then be reviewed by the entire subcommittee before sending to the steering committee. The steering
365 committee will compile, standardize, and expand (if needed) each recommendation.

366 *Action 21 – Develop accompanying materials*

367 The steering committee will convene to review all suggestions for accompanying materials from
368 panel pairs (Action 17, step 2) and make decisions on what is needed and feasible. The committee will
369 conduct an initial search for existing materials. Those materials that are deemed necessary will be brought to
370 a development panel meeting for discussion and consensus, and distributed to panel members for
371 development, adaptations, or for seeking permission to use existing materials.

372 **Phase 6: Review of CPG**

373 **Step 9: Review of CPG**

374 *Action 22 – Review of CPG:* The draft CPG will undergo three separate and sequential reviews: 1) internal
375 review by the development panel and the PFP advisory panel, 2) consultation open to all ESPNIC members,
376 and 3) external review by invited international experts, identified by the steering committee and development
377 panel.

378 The reviews will be conducted through an anonymous online survey using SurveyMonkey [34], with
379 a link sent by email from the steering committee chair using the ESPNIC’s internal distribution list and
380 personal contacts. Reviewers will evaluate the guideline for overall agreement and clarity, by section, using a
381 9-point Likert scale. Each section will have a comments area for missing information, suggestions for
382 modifications, setting-specific issues, and implementation implications.

383 The steering committee members will compile feedback from each review stage and revise the draft
384 accordingly. The changes by review will be documented and appended to the final CPG. These will be
385 discussed at a development panel meeting, with changes requiring 80% approval.

386 **Phase 7: Issue**

387 **Step 10: Publication of guideline**

388 The CPG development process will culminate in its publication in a peer-reviewed journal. The
389 outcomes from phases 1 - 4 will be published in a separate publication. The Right-Ad@pt checklist [70] will
390 be used to ensure the reporting of the adoption process. The target date for completing this CPG is June
391 2025. This CPG will be updated in five years or sooner if new evidence significantly impacts a
392 recommendation as monitored by the chair (IMD) using the search alerts.

393 **Discussion**

394 This protocol outlines a comprehensive methodological approach, using GRADE, to develop, adapt,
395 and contextualize a CPG for managing pain, sedation, delirium and IWS in critically ill children. By
396 addressing existing gaps in clinical knowledge and practice, the final CPG will provide updated, evidence-
397 based recommendations that incorporate emerging research and clinical advancements. The rigorous
398 methods include question and outcome prioritization, the use of the GRADE framework for evaluating
399 evidence quality and the strength of recommendations, and the creation of EtD tables. These EtD tables will
400 be made readily available to assist those in the interpretation of the CPG, support future CPG developers or
401 adaptors, and aid those responsible for updating this CPG. The methods used will ensure the creation of a
402 high-quality, transparent, and accessible CPG that will promote consistent, standardized care and improve
403 outcomes in PICUs.

404 This protocol describes the approach to GRADE-ADOLPMENT when EtD tables are unavailable,
405 offering a step-by-step process for those adopting this method for other CPG development and/or adaptation.
406 A key strength of this CPG is the inclusion of PFPs early and throughout all phases of the CPG development
407 process, addressing a notable limitation in previous CPGs [17]. This patient- and family-centered approach

408 considers a broad range of PFP experiences, enhancing the relevance and applicability of the CPG.
409 Additionally, the involvement of a wide range of experts and PFPs from across Europe ensures
410 representativeness and contextual sensitivity. The collaborative approach with continuous consensus
411 meetings aims to promote alignment and buy-in from all development panel members. The methodology
412 includes the addition of voting on summary recommendation, a novel approach to synthesizing
413 recommendations, as well as voting on research question and prioritizing outcomes, which addresses
414 methods previously missed in existing CPGs according to the GRADE approach. By including research
415 question voting based on clinical gaps identified both the literature and by the experts, this process helps to
416 identify key research areas for future investigation. A major strength is the comprehensive search approaches
417 and tailored search strategies to each recommendation and question. While other CPGs relied on a single
418 strategy to locate relevant literature and then distribute amongst questions [15-17], this approach employs
419 individual strategies to ensure thoroughness and transparency, even if it means encountering some
420 redundancy in search results.

421 There are several limitations, firstly, achieving consensus may be challenging due to diverse
422 perspectives across many stakeholders and across different languages. To facilitate consensus, surveys and
423 meetings will be used to gather input. Language barriers will be addressed by offering translated materials,
424 providing subtitles during Zoom meetings, and ensuring a bilingual speaker is available for direct translation
425 when necessary, in meetings. Another limitation inherent to the current state of knowledge is the availability
426 and quality of evidence for certain conditions or interventions, which may be limited. However,
427 consolidating this information in a transparent and accessible manner, combined with surveys from a large
428 development panel, will assist the formulation of credible recommendations. Additionally, using
429 standardized translation method for published studies in other languages may introduce new evidence
430 previously overlooked.

431 **Conclusion**

432 This protocol outlines a comprehensive approach to developing a CPG for managing pain, sedation,
433 delirium and IWS in pediatric critically ill patients, that will integrate the most up-to-date evidence and

434 diverse perspectives. By involving expert development panel members and PFPs, the resulting CPG will be
435 scientifically robust, patient-centered, and contextually relevant.

436 Voting on summary recommendations and question prioritization, along with a thorough literature
437 review to develop EtD tables, ensures that the CPG addresses important clinical issues. This CPG is designed
438 to promote optimal patient outcomes, making it valuable for clinicians, policymakers, patients and families.

439 **Acknowledgements**

440 We would like to acknowledge the expert development panel members who reviewed the protocol:
441 Gwenaëlle De Clifford-Faugère, Pieter De Cock, Saskia deWildt, Dmytro Dmytriiev, Juliane Engel, Paola
442 Claudia Fazio, Sylvia George, Isabelle Goyer, Anna Harðardóttir, Julia Harris, Klára Horváth, Erwin Ista,
443 Santiago Mencía, Tuuli Metsvaht, Maria Cristina Mondardini, Mehdi Oualha, Marie-Hélène Perez,
444 Krzysztof Pietrzkiwicz, Francesca Sperotto, Benjamin Wyness, and Nilufer Yalindag-Ozturk.

445 **Abbreviations**

446 PICU: pediatric intensive care unit
447 IWS: iatrogenic withdrawal syndrome
448 ESPNIC: European Society of Pediatric and Neonatal Intensive Care
449 CPG: clinical practice guideline
450 GRADE: Grading of Recommendations Assessment, Development and Evaluation
451 EtD: evidence to decision
452 PFP: Patient and family partner
453 COI: conflict of interest
454 AGREE: Appraisal of Guidelines for Research and Evaluation
455 AGREE-REX: Appraisal of Guidelines for Research and Evaluation Recommendation Excellence
456 AMSTAR 2: A MeaSurement Tool to Assess systematic Reviews 2
457 SoF: Summary of findings

458 **Declarations**

459 **Data availability:** Not applicable

460 **Code availability:** Not applicable

461 **Authors' contributions:** IM: Conceptualization, Methodology, Writing – original draft. ACT:
462 Conceptualization, Validation, Methodology, Writing – review & editing. CJ: Conceptualization, Validation,
463 Methodology, Writing – review & editing. AA: Conceptualization, Validation, Methodology, Writing –
464 review & editing. A-SR: Conceptualization, Methodology, Supervision, Validation, Writing – review &
465 editing. ESPNIC PaDIS consortium: Conceptualization, Writing – review & editing. ESPNIC PaDIS
466 consortium: Validation, Methodology, Writing – review & editing.

467 **References**

- 468 1. Kiesel LM, Bertsche A, Kiess W, Siekmeyer M, Bertsche T, Neining MP. Drug-Drug Interactions
469 Involving High-Alert Medications that Lead to Interaction-Associated Symptoms in Pediatric Intensive Care
470 Patients: A Retrospective Study. *Paediatric Drugs*. 2024;26(5):619-29. Doi: 10.1007/s40272-024-00641-x
- 471 2. Egbuta C, Mason KP. Current State of Analgesia and Sedation in the Pediatric Intensive Care Unit. *J*
472 *Clin Med*. 2021;10(9):1847. Doi: 10.3390/jcm10091847
- 473 3. Shajan N, Sharma M, Kaur G. Sedation in pediatric intensive care unit and its impact on outcomes of
474 ventilated children: a prospective observational study. *Egyptian Pediatric Association Gazette*.
475 2023;71(1):41.ARTN 4. Doi: 10.1186/s43054-023-00191-w
- 476 4. Censoplano NM, Barrett CS, Ing RJ, Reichert K, Rannie M, Kaufman J. Achieving Sustainability in
477 Reducing Unplanned Extubations in a Pediatric Cardiac ICU. *Pediatr Crit Care Med*. 2020;21(4):350-6. Doi:
478 10.1097/PCC.0000000000002193
- 479 5. Best KM, Wypij D, Asaro LA, Curley MA, Randomized Evaluation of Sedation Titration For
480 Respiratory Failure Study I. Patient, Process, and System Predictors of Iatrogenic Withdrawal Syndrome in
481 Critically Ill Children. *Crit Care Med*. 2017;45(1):e7-e15. Doi: 10.1097/CCM.0000000000001953

- 482 6. Alvarez RV, Palmer C, Czaja AS, Peyton C, Silver G, Traube C, et al. Delirium is a Common and
483 Early Finding in Patients in the Pediatric Cardiac Intensive Care Unit. *J Pediatr*. 2018;195:206-12. Doi:
484 10.1016/j.jpeds.2017.11.064
- 485 7. Stenkjaer RL, Egerod I, Moszkowicz M, Collet MO, Weis J, Ista E, et al. The parent perspective on
486 paediatric delirium and an associated care bundle: A qualitative study. *Journal of Advanced Nursing*.
487 2024;80(9):3734-44. Doi: 10.1111/jan.16048
- 488 8. Craske J, Carter B, Jarman I, Tume L. Parent's experiences of their child's withdrawal syndrome: a
489 driver for reciprocal nurse-parent partnership in withdrawal assessment. *Intensive Critical Care Nursing*.
490 2019;50:71-8. Doi: 10.1016/j.iccn.2018.09.001
- 491 9. Harris J, Ramelet AS, van Dijk M, Pokorna P, Wielenga J, Tume L, et al. Clinical recommendations
492 for pain, sedation, withdrawal and delirium assessment in critically ill infants and children: an ESPNIC
493 position statement for healthcare professionals. *Intensive Care Medicine*. 2016;42(6):972-86. Doi:
494 10.1007/s00134-016-4344-1
- 495 10. Daverio M, von Borell F, Ramelet AS, Sperotto F, Pokorna P, Brenner S, et al. Pain and sedation
496 management and monitoring in pediatric intensive care units across Europe: an ESPNIC survey. *Crit Care*.
497 2022;26(1):88. Doi: 10.1186/s13054-022-03957-7
- 498 11. Sperotto F, Ramelet AS, Daverio M, Mondardini MC, von Borell F, Brenner S, et al. Assessment
499 and management of iatrogenic withdrawal syndrome and delirium in pediatric intensive care units across
500 Europe: An ESPNIC survey. *Pharmacotherapy*. 2023;43(8):804-15. Doi: 10.1002/phar.2831
- 501 12. Ista E, Redivo J, Kananur P, Choong K, Colleti J, Jr., Needham DM, et al. ABCDEF Bundle
502 Practices for Critically Ill Children: An International Survey of 161 PICUs in 18 Countries. *Crit Care Med*.
503 2022;50(1):114-25. Doi: 10.1097/CCM.0000000000005168
- 504 13. Alvarado S, MacDonald I, Chanez V, Kudchadkar SR, Ista E, Ramelet A-S. Practices of assessment
505 of pain, sedation, iatrogenic withdrawal syndrome, and delirium in European paediatric intensive care units:
506 A secondary analysis of the European Prevalence of Acute Rehab for Kids in the paediatric intensive
507 care unit study. *Australian Critical Care*. 2024. Doi: 10.1016/j.aucc.2024.08.009
- 508 14. Steinberg E, Greenfield S, Wolman DM, Mancher M, Graham R. Clinical practice guidelines we can
509 trust. Washington: DC: National Academies Press; 2011.

- 510 15. Smith HAB, Besunder JB, Betters KA, Johnson PN, Srinivasan V, Stormorken A, et al. 2022 Society
511 of Critical Care Medicine Clinical Practice Guidelines on Prevention and Management of Pain, Agitation,
512 Neuromuscular Blockade, and Delirium in Critically Ill Pediatric Patients With Consideration of the ICU
513 Environment and Early Mobility. *Pediatr Crit Care Med*. 2022;23(2):e74-e110. Doi:
514 10.1097/PCC.0000000000002873
- 515 16. Amigoni A, Conti G, Conio A, Corno M, Fazio PC, Ferrero F, et al. Recommendations for analgesia
516 and sedation in critically ill children admitted to intensive care unit. *Journal of Anesthesia, Analgesia and*
517 *Critical Care*. 2022;2(1):9. Doi: 10.1186/s44158-022-00036-9
- 518 17. MacDonald I, Alvarado S, Marston MT, Gomez Tovar L, Chanez V, Favre E, et al. A systematic
519 review of clinical practice guidelines and recommendations for the management of pain, sedation, delirium
520 and iatrogenic withdrawal syndrome in pediatric intensive care. *Frontiers in Pediatrics*. 2023;11:1264717.
521 Doi: 10.3389/fped.2023.1264717
- 522 18. GRADE. GRADE handbook 2013. Available from: www.gradeworkinggroup.org.
- 523 19. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-
524 GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol*. 2011;64(4):383-94. Doi:
525 10.1016/j.jclinepi.2010.04.026
- 526 20. Mondardini MC, Sperotto F, Daverio M, Amigoni A. Analgesia and sedation in critically ill pediatric
527 patients: an update from the recent guidelines and point of view. *Eur J Pediatr*. 2023;182(5):2013-26. Doi:
528 10.1007/s00431-023-04905-5
- 529 21. Schunemann HJ, Wiercioch W, Brozek J, Etxeandia-Ikobaltzeta I, Mustafa RA, Manja V, et al.
530 GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of
531 trustworthy recommendations: GRADE-ADOLPMENT. *J Clin Epidemiol*. 2017;81:101-10. Doi:
532 10.1016/j.jclinepi.2016.09.009
- 533 22. Xun Y, Luo X, Lv M, Yang B, Lei R, Liu X, et al. Protocols for clinical practice guidelines. *J Evid*
534 *Based Med*. 2023;16(1):3-9. Doi: 10.1111/jebm.12502
- 535 23. Scott S, Cowl J, Schaefer C, Graham K, Fielding J, Howitt L, et al. How to recruit and support
536 patients and the public, and overcome barriers to their involvement in guideline development. *GIN Public*
537 *Toolkit: Patient and public involvement in guidelines: Guidelines International Network, Scotland; 2021.*

- 538 24. Brown J, Baer G, Cameron S, Jackson K, Lamouline C, Morley R, et al. Stakeholder involvement in
539 a Cochrane review of physical rehabilitation after stroke: Description and reflections. *Cochrane Evidence*
540 *Synthesis and Methods*. 2023;1(10):e12032. Doi: 10.1002/cesm.12032
- 541 25. Swiss Clinical Trial Organisation. PPI resources 2023 [Available from:
542 <https://www.scto.ch/en/patient-and-public-involvement/ppi-resources.html>.
- 543 26. SIGN. SIGN policy on conflict of interests with form for completion by individuals, carers,
544 voluntary organisations and members of the public to declare potential competing interests. n.d. p. 2
- 545 27. National Institute of Health and Care Excellence. Declarations of interest form (advisory
546 committees). In: Excellence NIOHaC, editor. 2022. p. 5
- 547 28. Rockliffe L. Including non-English language articles in systematic reviews: A reflection on
548 processes for identifying low-cost sources of translation support. *Research Synthesis Methods*. 2022;13(1):2-
549 5. Doi: 10.1002/jrsm.1508
- 550 29. National Institute of Health and Care Research. Payment guidance for researchers and professionals
551 2022 [updated August 2024. 1.6:[Available from: [https://www.nihr.ac.uk/documents/payment-guidance-for-](https://www.nihr.ac.uk/documents/payment-guidance-for-researchers-and-professionals/27392)
552 [researchers-and-professionals/27392](https://www.nihr.ac.uk/documents/payment-guidance-for-researchers-and-professionals/27392).
- 553 30. Schunemann HJ, Al-Ansary LA, Forland F, Kersten S, Komulainen J, Kopp IB, et al. Guidelines
554 International Network: Principles for Disclosure of Interests and Management of Conflicts in Guidelines.
555 *Annals of Internal Medicine*. 2015;163(7):548-53. Doi: 10.7326/M14-1885
- 556 31. Arumugam A, Phillips LR, Moore A, Kumaran SD, Sampath KK, Migliorini F, et al. Patient and
557 public involvement in research: a review of practical resources for young investigators. *BMC Rheumatol*.
558 2023;7(1):2. Doi: 10.1186/s41927-023-00327-w
- 559 32. Cochrane training. Using GRADEpro to perform a GRADE assessment and make a summary of
560 findings table 2023 [Available from: [https://training.cochrane.org/resource/using-gradepro-to-perform-grade-](https://training.cochrane.org/resource/using-gradepro-to-perform-grade-assessment-and-make-summary-of-findings-table)
561 [assessment-and-make-summary-of-findings-table](https://training.cochrane.org/resource/using-gradepro-to-perform-grade-assessment-and-make-summary-of-findings-table).
- 562 33. McMaster GRADE Centre. GRADE Learning Hub n.d. [Available from:
563 <https://macgrade.mcmaster.ca/grade-learning-hub/>.
- 564 34. SurveyMonkey Inc. San Mateo, California, USA
- 565 35. GRADEpro GDT. GRADEpro Guideline Development Tool. 2020

- 566 36. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing
567 the question and deciding on important outcomes. *Journal of clinical epidemiology*. 2011;64(4):395-400.
568 Doi: [10.1016/j.jclinepi.2010.09.012](https://doi.org/10.1016/j.jclinepi.2010.09.012)
- 569 37. MacDonald I, de Goumoens V, Marston M, Alvarado S, Favre E, Trombert A, et al. Effectiveness,
570 quality and implementation of pain, sedation, delirium, and iatrogenic withdrawal syndrome algorithms in
571 pediatric intensive care: a systematic review and meta-analysis. *Front Pediatr*. 2023;11:1204622. Doi:
572 [10.3389/fped.2023.1204622](https://doi.org/10.3389/fped.2023.1204622)
- 573 38. Fink EL, Maddux AB, Pinto N, Sorenson S, Notterman D, Dean JM, et al. A core outcome set for
574 pediatric critical care. *Critical care medicine*. 2020;48(12):1819-28. Doi: [10.1097/CCM.0000000000004660](https://doi.org/10.1097/CCM.0000000000004660)
- 575 39. Schults JA, Charles KR, Millar J, Rickard CM, Chopra V, Lake A, et al. Establishing a paediatric
576 critical care core quality measure set using a multistakeholder, consensus-driven process. *Critical Care and*
577 *Resuscitation*. 2024;26(2):71-9. Doi: [10.1016/j.ccrj.2024.01.002](https://doi.org/10.1016/j.ccrj.2024.01.002)
- 578 40. Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al. GRADE guidelines: 12.
579 Preparing summary of findings tables-binary outcomes. *Journal of clinical epidemiology*. 2013;66(2):158-72.
580 Doi: [10.1016/j.jclinepi.2012.01.012](https://doi.org/10.1016/j.jclinepi.2012.01.012)
- 581 41. Cochrane. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 2022. Available
582 from: www.training.cochrane.org/handbook.
- 583 42. AWMF o. S3-Leitlinie: Analgesie, Sedierung und Delirmanagement in der Intensivmedizin (DAS-
584 Leitlinie 2020) [Available from: <https://www.awmf.org/leitlinien/detail/ll/001-012.html>].
- 585 43. Schieveld JNM, de Graeff-Meeder E, Kalverdijk L, Gerver J, Knoester H, de Neef M, et al.
586 Multidisciplinaire richtlijn pediatriesch delier. Utrecht: De Tijdstroom; 2014.
- 587 44. Nederlandse Vereniging voor Anesthesiologie. Richtlijn - Postoperatieve pijn2012.
- 588 45. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer Review of
589 Electronic Search Strategies: 2015 Guideline Statement. *J Clin Epidemiol*. 2016;75:40-6. Doi:
590 [10.1016/j.jclinepi.2016.01.021](https://doi.org/10.1016/j.jclinepi.2016.01.021)
- 591 46. DeepL. DeepL Translator: 2017; [Available from: <https://www.deepl.com/translator>].

- 592 47. Borissov N, Haas Q, Minder B, Kopp-Heim D, von Gernler M, Janka H, et al. Reducing systematic
593 review burden using Deduklick: a novel, automated, reliable, and explainable deduplication algorithm to
594 foster medical research. *Syst Rev.* 2022;11(1):172. Doi: 10.1186/s13643-022-02045-9
- 595 48. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for
596 systematic reviews. *Syst Rev.* 2016;5(1):210. Doi: 10.1186/s13643-016-0384-4
- 597 49. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal
598 tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or
599 both. *BMJ.* 2017;358:j4008. Doi: 10.1136/bmj.j4008
- 600 50. Barker TH, Stone JC, Sears K, Klugar M, Tufanaru C, Leonardi-Bee J, et al. The revised JBI critical
601 appraisal tool for the assessment of risk of bias for randomized controlled trials. *JBI Evid Synth.*
602 2023;21(3):494-506. Doi: 10.11124/JBIES-22-00430
- 603 51. Barker TH, Habibi N, Aromataris E, Stone JC, Leonardi-Bee J, Sears K, et al. The revised JBI
604 critical appraisal tool for the assessment of risk of bias for quasi-experimental studies. *JBI Evidence*
605 *Synthesis.* 2024;22(3):378-88. Doi: 10.11124/JBIES-23-00268
- 606 52. Lockwood C, Munn Z, Porritt K. Qualitative research synthesis: methodological guidance for
607 systematic reviewers utilizing meta-aggregation. *Int J Evid Based Healthc.* 2015;13(3):179-87. Doi:
608 10.1097/XEB.0000000000000062
- 609 53. Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Systematic reviews of prevalence and incidence.
610 Joanna Briggs Institute reviewer's manual Adelaide, South Australia: The Joanna Briggs Institute. 2017;5:1-
611 5
- 612 54. Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, et al. Systematic reviews of
613 etiology and risk. Joanna Briggs Institute reviewer's manual. 5: The Joanna Briggs Institute Adelaide,
614 Australia; 2017. p. 217-69.
- 615 55. Gomersall JS, Jadotte YT, Xue Y, Lockwood S, Riddle D, Preda A. Conducting systematic reviews
616 of economic evaluations. *Int J Evid Based Healthc.* 2015;13(3):170-8. Doi:
617 10.1097/XEB.0000000000000063
- 618 56. Campbell JM, Kulgar M, Ding S, Carmody DP, Hakonsen SJ, Jadotte YT, et al. Diagnostic test
619 accuracy systematic reviews. In: Aromataris E, Munn Z, editors. *JBI manual for evidence synthesis.* 12020.

- 620 57. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: advancing
621 guideline development, reporting and evaluation in health care. *CMAJ*. 2010;182(18):E839-42. Doi:
622 10.1503/cmaj.090449
- 623 58. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the
624 sample size, median, range and/or interquartile range. *BMC Med Res Methodol*. 2014;14(1):135. Doi:
625 10.1186/1471-2288-14-135
- 626 59. StataCorp. *Stata Statistical Software: Release 17*. 17 ed. College Station, TX: StataCorp LLC; 2021
- 627 60. Simmonds M. Quantifying the risk of error when interpreting funnel plots. *Syst Rev*. 2015;4:24. Doi:
628 10.1186/s13643-015-0004-8
- 629 61. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4.
630 Rating the quality of evidence--study limitations (risk of bias). *J Clin Epidemiol*. 2011;64(4):407-15. Doi:
631 10.1016/j.jclinepi.2010.07.017
- 632 62. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7.
633 Rating the quality of evidence--inconsistency. *J Clin Epidemiol*. 2011;64(12):1294-302. Doi:
634 10.1016/j.jclinepi.2011.03.017
- 635 63. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8.
636 Rating the quality of evidence--indirectness. *J Clin Epidemiol*. 2011;64(12):1303-10. Doi:
637 10.1016/j.jclinepi.2011.04.014
- 638 64. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6.
639 Rating the quality of evidence--imprecision. *J Clin Epidemiol*. 2011;64(12):1283-93. Doi:
640 10.1016/j.jclinepi.2011.01.012
- 641 65. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating
642 the quality of evidence--publication bias. *Journal of Clinical Epidemiology*. 2011;64(12):1277-82.
643 Doi: 10.1016/j.jclinepi.2011.01.011
- 644 66. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines:
645 3. Rating the quality of evidence. *J Clin Epidemiol*. 2011;64(4):401-6. Doi: 10.1016/j.jclinepi.2010.07.015

- 646 67. Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al. GRADE guidelines:
647 9. Rating up the quality of evidence. J Clin Epidemiol. 2011;64(12):1311-6. Doi:
648 10.1016/j.jclinepi.2011.06.004
- 649 68. Mustafa RA, Garcia CAC, Bhatt M, Riva JJ, Vesely S, Wiercioch W, et al. GRADE notes: How to
650 use GRADE when there is "no" evidence? A case study of the expert evidence approach. J Clin Epidemiol.
651 2021;137:231-5. Doi: 10.1016/j.jclinepi.2021.02.026
- 652 69. Schunemann HJ, Zhang Y, Oxman AD, Expert Evidence in Guidelines G. Distinguishing opinion
653 from evidence in guidelines. BMJ. 2019;366:l4606. Doi: 10.1136/bmj.l4606
- 654 70. Song Y, Alonso-Coello P, Ballesteros M, Cluzeau F, Vernooij RW, Arayssi T, et al. A reporting tool
655 for adapted guidelines in health care: the RIGHT-Ad@ pt checklist. Annals of Internal Medicine.
656 2022;175(5):710-9.10. Doi: 7326/M21-4352

657 **Supporting information**

- 658 **S1 File. Checklist for guideline protocol.**
- 659 **S2 File. Declaration of interest form and conflict of interest: Expert panel.**
- 660 **S3 File. Information sheet: Patient and family partners.**
- 661 **S4 File. Expression of interest form: Patient and family partners.**
- 662 **S5 File. Recommendation table.**

1 – SET-UP

1) Establish groups: steering committee, development and advisory panels

- i. Formalize steering committee
- ii. Establish expert panel members on the development panel
- iii. Establish patient and family partners for two panels: 1) guideline development panel, and 2) advisory panel

2) Scoping the guideline

- iv. Scoping of population, condition, purpose, and users by expert panel members
- v. Input and validation by patient and family partners

2- PREPARATION

3) Voting and prioritization

- vi. Vote on summary recommendations
- vii. Research question prioritization
- viii. Patient and family partner input and validation
- ix. medRxiv preprint doi: <https://doi.org/10.1101/2024.10.12.24845389>; this version posted October 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](#).

4) Recommendation matching

- x. Update of clinical practice guideline systematic review
- xi. Matching research questions with existing recommendations

3 – SEARCH AND RETRIEVAL

5) Systematic search for evidence

- xii. Develop search strategies
- xiii. Conduct search and select studies for each question/recommendation
- xiv. Study appraisal
- xv. Data extraction and initial synthesis

4 – EVIDENCE SYNTHESIS

6) Evidence synthesis

- xvi. Summarizing the evidence
- xvii. Survey of current practice in the absence of evidence

5 - DEVELOPMENT

7) Recommendation development

- xviii. Recommendation drafting
- xix. Recommendation voting and approval

8) Draft guideline and accompanying content

- xx. Draft guideline
- xxi. Develop accompanying materials

6 - REVIEW

9) Review of guideline

- xxii. Internal, ESPNIC society-level, and external review

7 - ISSUE

10) Publication of guideline




Figure 2